{
    "2018-05-03": [
        [
            {
                "time": "2018-04-26",
                "original_text": "Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates",
                "features": {
                    "keywords": [
                        "Q1",
                        "Loss",
                        "Revenues",
                        "Beat",
                        "Estimates"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "We Were Winning the War Against Malaria",
                "features": {
                    "keywords": [
                        "Winning",
                        "War",
                        "Malaria"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates",
                "features": {
                    "keywords": [
                        "Q1",
                        "Loss",
                        "In Line",
                        "Revenues",
                        "Beat",
                        "Estimates"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "The Swiss Stock Market Pulled Back On Broad Weakness",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock Market",
                        "Pulled Back",
                        "Broad Weakness"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-19",
                "original_text": "Free Research Report as Novartisâ€™ Sales Jumped 10% and Core EPS Advanced 13%",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sales",
                        "Jumped",
                        "Core EPS",
                        "Advanced"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)",
                "features": {
                    "keywords": [
                        "Ligand",
                        "Earnings",
                        "Season"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-24",
                "original_text": "Roche wins reprieve as Novartis biosimilar delayed in U.S.",
                "features": {
                    "keywords": [
                        "Roche",
                        "wins",
                        "reprieve",
                        "Novartis",
                        "biosimilar",
                        "delayed",
                        "U.S."
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-23",
                "original_text": "Novartis biosimilar cancer drug hits U.S. regulatory bump",
                "features": {
                    "keywords": [
                        "Novartis",
                        "biosimilar",
                        "cancer",
                        "drug",
                        "U.S.",
                        "regulatory",
                        "bump"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}